Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker KYMR
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Mainolfi Nello Officer, Director | KYMR Kymera Therapeutics, Inc. | 30,000 | $3.4M | 10b5-1 | Oct 1, 2026 | — | Form 144 ↗ |
| Sep 4, 2026 | Brian Adams Officer | KYMR Kymera Therapeutics, Inc. | 6,371 | $747.2K | — | Sep 4, 2026 | Form 4 ↗ same day · 6,371 shares | Form 144 ↗ |
| Sep 2, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 10,879 | $1.3M | 10b5-1 | Sep 2, 2026 | — | Form 144 ↗ |
| Jul 7, 2026 | Mainolfi Nello Officer, Director | KYMR Kymera Therapeutics, Inc. | 50,000 | $6.0M | 10b5-1 | Jul 7, 2026 | Form 4 ↗ same day · 50,000 shares | Form 144 ↗ |
| Jul 2, 2026 | Mainolfi Nello Officer, Director | KYMR Kymera Therapeutics, Inc. | 80,000 | $9.1M | 10b5-1 | Jul 1, 2026 | Form 4 ↗ 5 days later · 50,000 shares | Form 144 ↗ |
| Jul 1, 2026 | Noah Goodman Officer | KYMR Kymera Therapeutics, Inc. | 3,389 | $388.6K | 10b5-1 | Jul 1, 2026 | Form 4 ↗ 1 day later · 3,389 shares | Form 144 ↗ |
| Jun 30, 2026 | Bruce N. Jacobs Officer | KYMR Kymera Therapeutics, Inc. | 77,109 | $8.4M | 10b5-1 | Jun 30, 2026 | Form 4 ↗ 2 days later · 77,109 shares | Form 144 ↗ |
| Jun 29, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 10,473 | $1.1M | 10b5-1 | Jun 29, 2026 | — | Form 144 ↗ |
| Jun 29, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 66,177 | $7.2M | 10b5-1 | Jun 29, 2026 | — | Form 144 ↗ |
| Jun 26, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 410,427 | $47.8M | 10b5-1 | Jun 26, 2026 | — | Form 144 ↗ |
| Jun 26, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 57,451 | $6.7M | 10b5-1 | Jun 26, 2026 | — | Form 144 ↗ |
| Jun 26, 2026 | BVF Partners L P/Il Affiliate of Director | KYMR Kymera Therapeutics, Inc. | 1.63M | $189.9M | — | Jun 26, 2026 | Form 4 ↗ same day · 1.63M shares | Form 144 ↗ |
| Jun 25, 2026 | Noah Goodman Officer | KYMR Kymera Therapeutics, Inc. | 5,000 | $499.4K | 10b5-1 | Jun 25, 2026 | Form 4 ↗ same day · 5,000 shares | Form 144 ↗ |
| Jun 25, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 67,329 | $6.7M | 10b5-1 | Jun 25, 2026 | — | Form 144 ↗ |
| Jun 25, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 480,992 | $48.0M | 10b5-1 | Jun 25, 2026 | — | Form 144 ↗ |
| Jun 24, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 118,178 | $11.6M | 10b5-1 | Jun 24, 2026 | — | Form 144 ↗ |
| Jun 24, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 16,542 | $1.6M | 10b5-1 | Jun 24, 2026 | — | Form 144 ↗ |
| Jun 23, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 173 | $17.2K | 10b5-1 | Jun 23, 2026 | — | Form 144 ↗ |
| Jun 23, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 1,235 | $122.8K | 10b5-1 | Jun 23, 2026 | — | Form 144 ↗ |
| Jun 22, 2026 | Noah Goodman Officer | KYMR Kymera Therapeutics, Inc. | 2,500 | $226.1K | 10b5-1 | Jun 22, 2026 | Form 4 ↗ same day · 2,500 shares | Form 144 ↗ |
| Jun 22, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 34,152 | $3.1M | 10b5-1 | Jun 22, 2026 | — | Form 144 ↗ |
| Jun 22, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 243,976 | $22.1M | 10b5-1 | Jun 22, 2026 | — | Form 144 ↗ |
| Jun 18, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 14,128 | $1.3M | 10b5-1 | Jun 18, 2026 | — | Form 144 ↗ |
| Jun 18, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 100,928 | $9.1M | 10b5-1 | Jun 18, 2026 | — | Form 144 ↗ |
| Jun 17, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 66,893 | $5.8M | 10b5-1 | Jun 17, 2026 | — | Form 144 ↗ |
| Jun 17, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 12,902 | $1.1M | 10b5-1 | Jun 17, 2026 | — | Form 144 ↗ |
| Jun 17, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 92,169 | $8.1M | 10b5-1 | Jun 17, 2026 | — | Form 144 ↗ |
| Jun 17, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | 11,741 | $1.0M | 10b5-1 | Jun 17, 2026 | Form 4 ↗ 5 days later · 478,198 shares | Form 144 ↗ |
| May 26, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 13,130 | $1.0M | 10b5-1 | May 26, 2026 | Form 4 ↗ 1 day later · 17,184 shares | Form 144 ↗ |
| May 26, 2026 | Jeremy G. Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 4,054 | $317.9K | — | May 26, 2026 | Form 4 ↗ 1 day later · 17,184 shares | Form 144 ↗ |
| May 11, 2026 | Elena Ridloff Director | KYMR Kymera Therapeutics, Inc. | 3,000 | $258.2K | 10b5-1 | May 11, 2026 | Form 4 ↗ same day · 3,000 shares | Form 144 ↗ |
| Apr 29, 2026 | Mainolfi Nello Officer, Director | KYMR Kymera Therapeutics, Inc. | 30,000 | $2.5M | 10b5-1 | Apr 29, 2026 | Form 4 ↗ same day · 30,000 shares | Form 144 ↗ |
| Apr 22, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 300 | $26.4K | 10b5-1 | Apr 22, 2026 | Form 4 ↗ 2 days later · 300 shares | Form 144 ↗ |
| Apr 22, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 88 | $7,750 | 10b5-1 | Apr 22, 2026 | — | Form 144 ↗ |
| Apr 22, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 12 | $1,057 | 10b5-1 | Apr 22, 2026 | — | Form 144 ↗ |
| Apr 15, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 1,300 | $116.8K | 10b5-1 | Apr 15, 2026 | Form 4 ↗ 1 day later · 6,551 shares | Form 144 ↗ |
| Apr 15, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 385 | $34.6K | 10b5-1 | Apr 15, 2026 | — | Form 144 ↗ |
| Apr 15, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 2,750 | $247.1K | 10b5-1 | Apr 15, 2026 | — | Form 144 ↗ |
| Apr 14, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 5,251 | $464.9K | 10b5-1 | Apr 14, 2026 | Form 4 ↗ 2 days later · 6,551 shares | Form 144 ↗ |
| Apr 14, 2026 | Bruce Booth Director | KYMR Kymera Therapeutics, Inc. | 24,000 | $2.1M | 10b5-1 | Apr 14, 2026 | Form 4 ↗ 2 days later · 9,494 shares | Form 144 ↗ |
| Apr 9, 2026 | Noah Goodman Officer | KYMR Kymera Therapeutics, Inc. | 11,611 | $1.0M | — | Apr 9, 2026 | Form 4 ↗ 1 day later · 10,264 shares | Form 144 ↗ |
| Apr 1, 2026 | Elena Ridloff Director | KYMR Kymera Therapeutics, Inc. | 4,600 | $383.1K | 10b5-1 | Apr 1, 2026 | Form 4 ↗ same day · 12,000 shares | Form 144 ↗ |
| Apr 1, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 14,640 | $1.2M | 10b5-1 | Apr 1, 2026 | Form 4 ↗ same day · 22,240 shares | Form 144 ↗ |
| Mar 31, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 7,600 | $604.0K | 10b5-1 | Mar 31, 2026 | Form 4 ↗ 1 day later · 22,240 shares | Form 144 ↗ |
| Mar 31, 2026 | Elena Ridloff Director | KYMR Kymera Therapeutics, Inc. | 7,400 | $588.2K | 10b5-1 | Mar 31, 2026 | Form 4 ↗ 1 day later · 12,000 shares | Form 144 ↗ |
| Mar 23, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 115,977 | $9.0M | 10b5-1 | Mar 23, 2026 | Form 4 ↗ 2 days later · 115,977 shares | Form 144 ↗ |
| Mar 20, 2026 | Pamela Esposito Director | KYMR Kymera Therapeutics, Inc. | 2,500 | $198.9K | 10b5-1 | Mar 20, 2026 | Form 4 ↗ same day · 2,500 shares | Form 144 ↗ |
| Mar 11, 2026 | Jeremy Chadwick Officer | KYMR Kymera Therapeutics, Inc. | 25,758 | $2.2M | 10b5-1 | Mar 11, 2026 | Form 4 ↗ same day · 25,758 shares | Form 144 ↗ |
| Mar 2, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 25,000 | $2.3M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
| Mar 2, 2026 | Atlas Venture Fund X, LP Shareholder | KYMR Kymera Therapeutics, Inc. | 200,000 | $18.3M | 10b5-1 | Mar 2, 2026 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 11:01 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances